In this informative webinar attendees will gain insights into advances in covalent drug discovery. The discovery of targeted covalent modulators has attracted considerable interest over the past years, driven in part by a better understanding of target engagement and pharmacodynamics, combined with new innovations in the chemistry of electrophilic moieties.
In this webinar, the featured speaker will discuss the basic principles of covalent drug discovery and will provide examples of targeted covalent modulators that have been approved by the Food and Drug Administration (FDA) or are in late-stage clinical trials. Later, he will summarize the diversity of warheads and will review the patent activity in this competitive space over the past few years.
In addition, the featured speaker will discuss several case studies and how X-Chem can help scientists rapidly advance challenging projects using this exciting and innovative drug discovery modality.
Join this webinar to get insights into covalent drug discovery and targeted covalent modulators that have been approved by the FDA.
Philip Carpino, PhD, Executive Director, Medicinal Chemistry, X-Chem
Phil Carpino is currently an Executive Director at X-Chem Montreal, overseeing medicinal chemistry and drug discovery services for client companies. He has worked in all areas of small molecule drug discovery research, from target identification/validation to hit-to-lead discovery to end-stage compound optimization. He began his professional career at Pfizer where he played a key role in the development of numerous clinical drug candidates to treat various metabolic diseases. He was part of an exploratory project team that discovered a new mechanism involving ribosomal stalling to modulate an undruggable target.
He is the inventor of Capromorelin, a drug originally investigated as a treatment for frailty in human clinical trials, but subsequently out-licensed by Pfizer to Aratana (now Elanco) and brought to market as Entyce™/Elura™ for stimulating appetite in companion animals with cachexia. Phil later joined Recursion Pharmaceuticals located in Salt Lake City, developing drugs for rare diseases, and then Janssen Pharmaceuticals where he was involved in discovering tissue-targeted drugs to treat ocular and pulmonary diseases.
Phil earned his BA in Chemistry from Reed College in Portland and received a PhD in organic chemistry from Harvard University, working under the direction of Nobel laureate Professor E. J. Corey on the syntheses of natural products. He is an inventor/author of 43 issued US patents and 53 scientific articles.
Who Should Attend?
This webinar will appeal to professionals in the following fields:
- Medicinal Chemists
- Pharmaceutical Scientists who participate in exploratory chemistry and target ID and validation (TIDVAL) teams
What You Will Learn
Attendees will gain insights into:
- The advances in the field of covalent drug discovery
- The basic principles of covalent drug discovery
- The examples of targeted covalent modulators that have been approved by the FDA or are in late-stage clinical trials
- The patent activity in this competitive space over the past few years
X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotech companies. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can take those leads and progress them to clinical candidates with unmatched speed. Throughout the process, X-Chem’s advanced proprietary artificial intelligence (AI) technology accelerates all steps in the process. X-Chem also provides libraries, reagents and informatic tools to allow DEL operators to get the most out of their DEL platform. X-Chem empowers its partners to effectively build drug pipelines from target to clinical candidate, enhanced with AI. For further information, please visit www.x-chemrx.com.